278 related articles for article (PubMed ID: 30478958)
41. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells.
Hirai T; Saito S; Fujimori H; Matsushita K; Nishio T; Okayasu R; Masutani M
Biochem Biophys Res Commun; 2016 Sep; 478(1):234-240. PubMed ID: 27425251
[TBL] [Abstract][Full Text] [Related]
42. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
43. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
44. Alternative end-joining and classical nonhomologous end-joining pathways repair different types of double-strand breaks during class-switch recombination.
Cortizas EM; Zahn A; Hajjar ME; Patenaude AM; Di Noia JM; Verdun RE
J Immunol; 2013 Dec; 191(11):5751-63. PubMed ID: 24146042
[TBL] [Abstract][Full Text] [Related]
45. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
46. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1.
Orsburn B; Escudero B; Prakash M; Gesheva S; Liu G; Huso DL; Franco S
Mol Cell Biol; 2010 May; 30(10):2341-52. PubMed ID: 20231360
[TBL] [Abstract][Full Text] [Related]
47. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
48. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
[TBL] [Abstract][Full Text] [Related]
49. PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer.
Huang M; Chen L; Guo Y; Ruan Y; Xu H
J Transl Med; 2023 Jul; 21(1):445. PubMed ID: 37415147
[TBL] [Abstract][Full Text] [Related]
50. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
[TBL] [Abstract][Full Text] [Related]
51. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
52. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
53. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
[TBL] [Abstract][Full Text] [Related]
54. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks.
Ma J; Zhou Y; Pan P; Yu H; Wang Z; Li LL; Wang B; Yan Y; Pan Y; Ye Q; Liu T; Feng X; Xu S; Wang K; Wang X; Jian Y; Ma B; Fan Y; Gao Y; Huang H; Li L
Nat Commun; 2023 Mar; 14(1):1810. PubMed ID: 37002234
[TBL] [Abstract][Full Text] [Related]
55. Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
Zhang W; van Weerden WM; de Ridder CMA; Erkens-Schulze S; Schönfeld E; Meijer TG; Kanaar R; van Gent DC; Nonnekens J
Prostate; 2019 Mar; 79(4):390-402. PubMed ID: 30520109
[TBL] [Abstract][Full Text] [Related]
56. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
57. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
58. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
59. Parp1-XRCC1 and the repair of DNA double strand breaks in mouse round spermatids.
Ahmed EA; de Boer P; Philippens ME; Kal HB; de Rooij DG
Mutat Res; 2010 Jan; 683(1-2):84-90. PubMed ID: 19887075
[TBL] [Abstract][Full Text] [Related]
60. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]